All In Biotech

Drug Trial Radar · NCT01949129

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Apr 2013

Primary completion

Jun 1, 2030

Study completion Jun 1, 2030

Sponsor

Lead sponsor
St. Anna KinderkrebsforschungAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ALL SCTped Forum; European Society for Blood and Marrow Transplantation; ALL-BFM Study Group; Assistance Publique - Hôpitaux de Paris; Dutch Childhood Oncology Group; Swiss Pediatric Oncology Group; Australian & New Zealand Children's Haematology/Oncology Group
First posted
Sep 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 month, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen. The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.

Conditions

  • Acute Lymphoblastic Leukaemia

Interventions

  • VP16Drug

    60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning

  • TBIRadiation

    2 x 2Gy/day , 3 days (total 12Gy)

  • ThiotepaDrug

    2x5 mg/kg BW, 1 day

  • TreosulfanDrug

    14g/m² BS, 3 days

  • FludarabineDrug

    30 mg/m² BS, 5 days

  • BusulfanDrug

    iV, dosage according therapeutic drug monitoring, 4 days

  • ATG ThymoglobulinDrug

    MD: ATG Thymo: 2,5mg/kg BW/d 3 days.

  • CyclophosphamideDrug

    as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna

  • GrafalonDrug

    MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) Stratum 1a (randomisation TBI+ chemo-conditioning vs. chemo-conditioning only)Time frame: first: 18 months after inclusion of first patient, afterwards annually up to 10 years
  2. Event free survival (EFS) Stratum 2 (mismatched donor transplantation)Time frame: first: 18 months after inclusion of first patient, afterwards annually up to 10 years
  3. Overall Survival (OS), Stratum 1b: MSD/MD without randomisationTime frame: first: 18 months after inclusion of first patient, afterwards annually up to 10 years

Locations

119 sites in 31 countries. Site status is shown where the registry gives one.

  • Hospital de Pediatria "Juan P. Garrahan" Combate de Los Pozos N°1800 CABA

    Buenos Aires, Argentina · Recruiting

  • Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit

    La Plata, Argentina · Recruiting

  • Children's Cancer Centre The Royal Children's Hospital

    Melbourne, Australia · Active not recruiting

  • Princess Margaret Hospital for Children

    Perth, Australia · Active not recruiting

  • Sydney Children's Hospital

    Randwick, Australia · Active not recruiting

  • Lady Cilento Children's Hospital

    South Brisbane, Australia · Active not recruiting

  • The Children's Hospital at Westmead Oncology Unit

    Sydney, Australia · Active not recruiting

  • Universitätsklinik für Kinder- und Jugendheilkunde, Abt. f. Hämato-Onkologie

    Graz, Austria · Recruiting

  • Universitätsklinik für Kinder- und Jugendheilkunde

    Innsbruck, Austria · Recruiting

  • St. Anna Children's Hospital, Vienna, Austria

    Vienna, Austria · Recruiting

  • Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

    Minsk, Belarus · Active not recruiting

  • Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)

    Brussels, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc (UCL) Hématologie et oncologie pédiatrique

    Brussels, Belgium · Recruiting

  • University Hospital Gent Pediatrische hemato-oncologie

    Ghent, Belgium · Recruiting

  • University Hospitals Leuven Kinderhemato-oncologie

    Leuven, Belgium · Recruiting

  • Centre Hospitalier Universitaire de Liège Domaine Universitaire du Sart Tilman

    Liège, Belgium · Recruiting

  • Alberta Children's Hospital Division of Pediatric Oncology

    Calgary, Canada · Active not recruiting

  • Montreal Children's Hospital

    Montral, Canada · Active not recruiting

  • CHU Sainte-Justine Hematology-Oncology Division

    Montreal, Canada · Active not recruiting

  • Hospital for Sick Children University of Toronto Division of Haematology/Oncology

    Toronto, Canada · Completed

  • BC Children's Hospital

    Vancouver, Canada · Completed

  • CancerCare Manitoba/University of Manitoba

    Winnipeg, Canada · Withdrawn

  • Hospital Dr Luis Calvo Mackenna

    Santiago, Chile · Recruiting

  • Department of Pediatrics, UHC Zagreb

    Zagreb, Croatia · Recruiting

  • Department of Pediatric Hematology and Oncology Teaching Hospital Motol, 2nd Medical School, Charles University

    Prague, Czechia · Recruiting

  • Paediatric Stem Cell Transplant and Immune Deficiency, Dept. for children and adolescents 4072, Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, Univ. of Helsinki

    Helsinki, Finland · Completed

  • CHU Bordeaux

    Bordeaux, France · Active not recruiting

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France · Active not recruiting

  • CHU Grenoble - Clinique Universitaire de Pédiatrie, Hôpital Couple Enfant

    Grenoble, France · Active not recruiting

  • CHRU Lille, Service d'Hématologie Pédiatrique

    Lille, France · Active not recruiting

  • IHOP / Lyon, Service Hématologie et d'Oncologie pédiatrique

    Lyon, France · Active not recruiting

  • Hopital la Timone Adulte

    Marseille, France · Active not recruiting

  • Hopital Arnaud de Villeneuve

    Montpellier, France · Active not recruiting

  • CHU Nancy - Hopital d'Enfants

    Nancy, France · Active not recruiting

  • CHU Nantes, Service d'onco hémato pédiatrie

    Nantes, France · Active not recruiting

  • Hôpital Robert Debré

    Paris, France · Active not recruiting

  • CHU de Rennes, Serive d'Onco-Pédiatrie

    Rennes, France · Active not recruiting

  • CHU de Rouen, Hopital des Enfants, Service d' Immuno-Hématologie Oncologie Pédiatrique

    Rouen, France · Active not recruiting

  • CHU Strasbourg, Service d'hématologie et d'oncologie pédiatrique

    Strasbourg, France · Active not recruiting

Showing 40 of 119 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.